Bausch Health Companies Inc (NYSE:BHC) EVP Christina Ackermann sold 3,968 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $24.81, for a total transaction of $98,446.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of BHC opened at $22.91 on Thursday. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. The stock’s 50 day simple moving average is $23.16. Bausch Health Companies Inc has a 1-year low of $17.20 and a 1-year high of $28.45. The stock has a market cap of $8.15 billion, a PE ratio of 5.57, a price-to-earnings-growth ratio of 0.52 and a beta of 0.78.
Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Monday, May 6th. The company reported $1.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.14. Bausch Health Companies had a negative net margin of 19.27% and a positive return on equity of 47.01%. The business had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $2.03 billion. During the same period last year, the company posted $0.89 EPS. The company’s revenue was up 1.1% on a year-over-year basis. On average, equities analysts expect that Bausch Health Companies Inc will post 4.19 earnings per share for the current year.
BHC has been the subject of a number of research analyst reports. Piper Jaffray Companies set a $29.00 target price on shares of Bausch Health Companies and gave the company a “buy” rating in a report on Tuesday, June 11th. Mizuho set a $45.00 target price on shares of Bausch Health Companies and gave the company a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald set a $32.00 target price on shares of Bausch Health Companies and gave the company a “buy” rating in a report on Friday, May 31st. JPMorgan Chase & Co. increased their target price on shares of Vermilion Energy from C$42.00 to C$43.00 in a report on Monday, May 13th. Finally, Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a report on Monday. Three analysts have rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $27.65.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Read More: Conference Calls and Individual Investors
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.